Table 5.
Clinical results of patients according to viral co-infection with rhinovirus.
| Characteristic | SARS-CoV-2 | RSV | hBoV | ADE | Influenza | hPVI | hMPV | SARS-Like | >3 viruses | χ2 | P valour |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fever | 20% | 50% | 66.66% | 25% | 25% | 28.57% | 75% | 20% | 73.91% | 21.92 | 0.009 |
| RN/R | 26.08% | 18.75% | 66.66% | 62.5% | 62.5% | 40% | 25% | 0% | 26.08% | 25.01 | 0.003 |
| Cough | 55% | 68.75% | 58.33% | 87.5% | 62.5% | 71.42% | 75% | 20% | 86.95% | 28.09 | < 0.001 |
| Sneezing | 10% | 6.25% | 25% | 0% | 12.5% | 42.85% | 0% | 0% | 0% | 14.63 | 0.101 |
| Wheezing | 20% | 43.75% | 75% | 50% | 37.5% | 28.57% | 25% | 80% | 30.43% | 17.79 | 0.038 |
| D/T | 40% | 43.75% | 66.66% | 62.5% | 12.5% | 28.57% | 75% | 80% | 60.87% | 50.38 | < 0.001 |
| PNM | 75% | 68.75% | 66.66% | 62.5% | 57.14% | 28.57% | 50% | 100% | 56.52% | 17.17 | 0.046 |
| AVB | 9.52% | 12.5% | 16.66% | 22.22% | 12.5% | 14.28% | 25% | 0% | 8.69% | 12.08 | 0.208 |
| O2 Use | 14.28% | 31.25% | 16.66% | 22.22% | 0% | 0% | 0% | 40% | 8.69% | 51.68 | < 0.001 |
| Altered chest X-ray | 70% | 50% | 58.33% | 37,5% | 37.5% | 14.28% | 75% | 100% | 60.87% | 23.39 | 0.005 |
| NIV | 30% | 12.5% | 50% | 0% | 14.28% | 0% | 0% | 0% | 17.39% | 17.04 | 0.048 |
| IMV | 35% | 18.75% | 25% | 0% | 0% | 0% | 25% | 0% | 13.04% | 21.56 | 0.01 |
| Death | 5% | 6.66% | 16.66% | 0% | 0% | 0% | 25% | 0% | 4.76% | 8.905 | 0.446 |
Abbreviations: M (months), RN/R (runny nose/rhinorrhea), D/T (dyspnea/tachypnoea), PNM (pneumonia), AVB (acute viral bronchiolitis), NIV (Non-Invasive Ventilation), IMV (Intermittent Mandatory Ventilation).
RSV (Respiratory Syncytial virus); hBoV (Bocavirus); ADE (Adenovirus); hPVI (parainfluenza); hMPV (metapneumovirus)